← All trials
NCT06348888
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 10, 2024
- Primary completion
- Jun 12, 2024
- Completion date
- Jun 12, 2024
- First posted
- Apr 5, 2024
- Last posted
- Jun 20, 2024
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BayerLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.